Olon S.p.A. is going to finalise its development of API OLAPARIB. The product is a poly-ADP-Ribose polymerase inhibitor and it is used for the treatment of ovarian cancer.
P&R and Infa Group shareholders have reached the deal closing for the transaction of 100% Infa shares to Olon SpA.
Olon is one of the largest European developers and manufacturers, supplying APIs for the pharmaceutical industry worldwide both, for Generic as well as for contract manufacturing.
OLON owns 5 manufacturing sites in northern Italy (Rodano, Settimo Torinese, Garbagnate Milanese, Mulazzano and Dorno) with more than 800 employees while INFA Group, with more than 400 employees, has 2 manufacturing sites in Italy, Labochim and Sifavitor, and 1 in Spain, Derivados Químicos.
The acquisition will broaden and diversify the portfolio by doubling it up to more than 200 Generic products and will strengthen the presence in the Contract Development & Manufacturing Organization (CDMO).
OLON 2015 revenue were above € 200 mln. The 2016 total pro-forma revenue expected combining Olon and INFA will be well over € 300 mln, confirming the birth of a significant player in Europe as well as in the US.
"The acquisition of INFA will provide an established custom synthesis presence with customers worldwide and will strengthen our Generic position by adding a large amount of products positioning OLON as one of the largest player in Europe," said Paolo Tubertini, OLON CEO.
“INFA will be complementary to OLON in the Generic field and add new technologies and a broad base capabilities and expertise in the field of contract manufacturing for the development of new intermediates and API”, said Luca Mantovani, Infa Group CEO
Strategic advantages of the acquisition
The merge of Olon and Infa will expand Olon products portfolio already including, among others, fermented and semi-synthetic API, HPAPIs and cytotoxic compounds, controlled substances, retinoids, antivirals, biologics, recombinant peptides.
Olon and Infa will have available about 130 Active US Drug Master Files (DMFs) and more than 50 EU Certificates of Suitability (COS) or Compliance with the European Pharmacopoeia (CEP) and will rely on 8 manufacturing facilities self-identified under GDUFA.
The acquisition will strengthen its services to CDMO customers from the early clinical phases up to the commercial manufacturing, thanks to an highly qualified R&D team, a QA operating under the highest international standards and an experienced Regulatory team supporting the filings globally.
P&R Group is one of the major Italian groups in the chemical-pharmaceutical industry, headquartered in Rodano (Milan), with revenues in 2015 for more than € 550 million, of which more than 70% by exports.
P&R Group holds SIR, Fidia Farmaceutici and Olon, with 2,000 employees.
P&R Group is recognized as a player who contributed significantly to the history of the Italian chemical industry, with its activities dating back to early 20th Century.
In April 2016 Olon’s Rodano site was audited as a supplier Company with a SMETA Audit (Sedex Members Ethical Trade Audit) with positive outcome.
The Audit report is available for members on Sedex database or upon request.